Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Hansa Biopharma AB (publ)    HNSA   SE0002148817

HANSA BIOPHARMA AB (PUBL)

(HNSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Hansa Biopharma : certified as a Great Place to Work

09/11/2020 | 02:01am EST

Based on the results of a company-wide employee survey and a review of policies, Hansa Biopharma has been officially awarded the Great Place to Work certificate by the Great Place to Work Institute

Lund, SwedenSeptember 11, 2020. Hansa Biopharma AB ("Hansa"), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its certification as a Great Place to Work 2020 by the independent institute Great Place to Work®, a global authority on workplace culture and leadership behaviour. The certification was primarily based on ratings provided by Hansa employees in an anonymous survey that assesses perspectives on leadership, organizational culture and trust.

"We are very happy and proud to be officially designated a Great Place to Work. Our mission -  to develop innovative, lifesaving and life altering immunomodulating therapies, bring these to the patients with rare diseases who need them, and generate value to society at large -  depends on our ability to attract, develop and retain the very best talent in the industry. This certification reflects our efforts to build a strong organization as we continue our growth trajectory and transition into a commercial-stage company", says Søren Tulstrup, President & CEO of Hansa Biopharma.

Ninety-six percent of Hansa employees participated in the Great Place to Work survey. Great pride in joint achievements, team-spirit and managerial trust were identified as main strengths of the company.

About Great Place to Work® 
Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees around the world and used those deep insights to define what makes a great workplace: trust. Their unparalleled benchmark data is used to recognize Great Place to Work-Certified™ companies and the Best Workplaces™ in more than 60 countries, including the 100 Best Companies to Work For® and World's Best list published annually in Fortune. Everything they do is driven by the mission to build a better world by helping every organization become a Great Place to Work For All™. To learn more, visit greatplacetowork.com. (http://www.greatplacetowork.com) 

For further information, please contact:
Anne Säfström Lanner
Chief Human Resources Officer 
Hansa Biopharma 
M: +46 (0) 709-298 133
E:anne.safstromlanner@hansabiopharma.com

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, gene therapy and cancer. The Company's lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020. Hansa's research and development program is advancing the Company's enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-ab-certified-as-a-great-place-to-work-,c3192360

https://mb.cision.com/Main/1219/3192360/1305254.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
HANSA BIOPHARMA AB (PUBL) -0.16% 183.7 Delayed Quote.-23.46%
HANSAE YES24 HOLDINGS CO., LTD 2.79% 7380 End-of-day quote.-3.66%
All news about HANSA BIOPHARMA AB (PUBL)
01/11HANSA BIOPHARMA : Forecasts FY20 Operating Loss to Widen
MT
01/11HANSA BIOPHARMA : provides business update incl. certain key financials ahead of..
AQ
2020HANSA BIOPHARMA :  Biopharma to present at the 39th Annual J.P. Morgan Healthcar..
AQ
2020HANSA BIOPHARMA : Nomination Committee formed
AQ
2020Hansa Biopharma interim report Jan-Sep 2020
AQ
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
PU
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
AQ
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
PU
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
AQ
2020HANSA BIOPHARMA : certified as a Great Place to Work
AQ
More news
Financials
Sales 2020 35,8 M 4,30 M 4,30 M
Net income 2020 -396 M -47,7 M -47,7 M
Net cash 2020 1 385 M 166 M 166 M
P/E ratio 2020 -19,6x
Yield 2020 -
Capitalization 8 183 M 980 M 984 M
EV / Sales 2020 190x
EV / Sales 2021 74,4x
Nbr of Employees 80
Free-Float 95,9%
Chart HANSA BIOPHARMA AB (PUBL)
Duration : Period :
Hansa Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANSA BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 295,67 SEK
Last Close Price 184,00 SEK
Spread / Highest target 123%
Spread / Average Target 60,7%
Spread / Lowest Target 3,26%
EPS Revisions
Managers and Directors
NameTitle
Søren Tulstrup President & Chief Executive Officer
Ulf Arne Wiinberg Chairman
Christian Kjellman Chief Operating & Scientific Officer
Donato Spota Chief Financial Officer
Achim Kaufhold Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
HANSA BIOPHARMA AB (PUBL)-23.46%980
MODERNA, INC.19.79%49 519
LONZA GROUP AG4.32%49 499
CELLTRION, INC.-13.37%38 562
IQVIA HOLDINGS INC.6.35%36 531
SEAGEN INC.8.94%34 515